Published in J Am Coll Surg on April 01, 1998
History of clinical transplantation. World J Surg (2000) 0.91
Hepatic and intestinal transplantation at the University of Pittsburgh. Clin Transpl (1998) 0.78
The birth of clinical organ transplantation. J Am Coll Surg (2001) 0.76
Regulation of immune reactivity and tolerance by antigen migration and localization: with particular reference to allo- and xenotransplantation. Transplant Proc (1999) 0.75
Tolerance, danger, and the extended family. Annu Rev Immunol (1994) 14.94
Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
THE REVERSAL OF REJECTION IN HUMAN RENAL HOMOGRAFTS WITH SUBSEQUENT DEVELOPMENT OF HOMOGRAFT TOLERANCE. Surg Gynecol Obstet (1963) 8.04
Immunology taught by viruses. Science (1996) 4.82
Baboon-to-human liver transplantation. Lancet (1993) 4.01
A biological role for the major histocompatibility antigens. Lancet (1975) 3.40
The lost chord: microchimerism and allograft survival. Immunol Today (1996) 2.81
RENAL HETEROTRANSPLANTATION FROM BABOON TO MAN: EXPERIENCE WITH 6 CASES. Transplantation (1964) 2.78
Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev (1997) 2.58
RENAL HETEROTRANSPLANTATION IN MAN. Ann Surg (1964) 2.56
Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nat Med (1995) 2.31
Evolutionary relationship between the natural anti-Gal antibody and the Gal alpha 1----3Gal epitope in primates. Proc Natl Acad Sci U S A (1987) 2.27
Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. Transplantation (1993) 2.17
Baboon-to-human cardiac xenotransplantation in a neonate. JAMA (1985) 1.98
The biological basis of and strategies for clinical xenotransplantation. Immunol Rev (1994) 1.56
Transplantation of discordant xenografts: a challenge revisited. Immunol Today (1996) 1.27
Evolution and pathophysiology of the human natural anti-alpha-galactosyl IgG (anti-Gal) antibody. Springer Semin Immunopathol (1993) 1.25
Delayed xenograft rejection. Immunol Today (1996) 1.23
Donor species complement after liver xenotransplantation. The mechanism of protection from hyperacute rejection. Transplantation (1994) 1.21
Oligosaccharides and discordant xenotransplantation. Immunol Rev (1994) 1.18
Reduction in the level of Gal(alpha1,3)Gal in transgenic mice and pigs by the expression of an alpha(1,2)fucosyltransferase. Proc Natl Acad Sci U S A (1996) 1.12
Combined transgenic expression of alpha-galactosidase and alpha1,2-fucosyltransferase leads to optimal reduction in the major xenoepitope Galalpha(1,3)Gal. Proc Natl Acad Sci U S A (1997) 1.08
Xenotransplantation: recent progress and current perspectives. Curr Opin Immunol (1996) 1.01
Histocompatibility requirements of heart and skin grafts in rats. Transplant Proc (1971) 0.91
Expression of human decay accelerating factor or membrane cofactor protein genes on mouse cells inhibits lysis by human complement. Transpl Int (1992) 0.84
Lack of susceptibility of baboons to infection with hepatitis B virus. Transplantation (1996) 0.82
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24
The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
Bone marrow as a potential source of hepatic oval cells. Science (1999) 8.52
Kidney transplantation under FK 506. JAMA (1990) 7.45
Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92
Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54
Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39
Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science (2000) 5.38
Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01
Liver transplantation (1). N Engl J Med (1989) 4.53
Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32
Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
Baboon-to-human liver transplantation. Lancet (1993) 4.01
Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85
Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63
Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats. Transplantation (1995) 3.63
Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57
Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc (1987) 3.55
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43
Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36
Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34
Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29
Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26
The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
Dendritic cell loss from nonlymphoid tissues after systemic administration of lipopolysaccharide, tumor necrosis factor, and interleukin 1. J Exp Med (1995) 3.16
Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen. Am J Pathol (1985) 3.16
Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation (1993) 3.13
Orthotopic liver transplantation in dogs receiving FK-506. Transplant Proc (1987) 3.11
Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. N Engl J Med (1992) 2.98
Outcome analysis of 71 clinical intestinal transplantations. Ann Surg (1995) 2.95
Liver transplantation (2). N Engl J Med (1989) 2.93
Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res (1997) 2.91
Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg (2000) 2.91
Allospecificity of activated T cells grown from endomyocardial biopsies from heart transplant patients. Transplantation (1986) 2.82
Functional screening of 2 Mb of human chromosome 21q22.2 in transgenic mice implicates minibrain in learning defects associated with Down syndrome. Nat Genet (1997) 2.81
The lost chord: microchimerism and allograft survival. Immunol Today (1996) 2.81
Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81
Cadaveric small bowel and small bowel-liver transplantation in humans. Transplantation (1992) 2.75
THE IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 IN RATS RECEIVING HETEROTOPIC CARDIAC ALLOGRAFTS. Surg Res Commun (1987) 2.75
Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66
The prognostic value of kidney transplant center report cards. Am J Transplant (2013) 2.64
A review of adult and pediatric post-transplant liver pathology. Pathol Annu (1987) 2.62
FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation (1994) 2.50
Propagation of dendritic cell progenitors from normal mouse liver using granulocyte/macrophage colony-stimulating factor and their maturational development in the presence of type-1 collagen. J Exp Med (1994) 2.48
Hepatotrophic effects of FK506 in dogs. Transplantation (1991) 2.39
Toxicology of FK-506 in the Lewis rat. Transplant Proc (1987) 2.37
Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31
The effects of FK 506 on renal function after liver transplantation. Transplant Proc (1990) 2.31
Pigmented villonodular synovitis (giant-cell tumor of the tendon sheath and synovial membrane). A review of eighty-one cases. J Bone Joint Surg Am (1984) 2.31
FK 506 in clinical kidney transplantation. Transplant Proc (1991) 2.29
Differential survival of hamster-to-rat liver and cardiac xenografts under FK 506 immunosuppression. Transplant Proc (1991) 2.28
Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant (2012) 2.28
Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25
Human islet isolation and allotransplantation in 22 consecutive cases. Transplantation (1992) 2.20
Transplantation milestones. Viewed with one- and two-way paradigms of tolerance. JAMA (1995) 2.20
Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. Transplantation (1993) 2.17
Induction of liver, heart, and multivisceral graft acceptance with a short course of FK 506. Transplant Proc (1990) 2.15
Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. Transplantation (1993) 2.14
FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in rats. Transplantation (1990) 2.13
Wnt-5a has tumor suppressor activity in thyroid carcinoma. Oncogene (2005) 2.11
Modulation of nitrogen oxide synthesis in vivo: NG-monomethyl-L-arginine inhibits endotoxin-induced nitrate/nitrate biosynthesis while promoting hepatic damage. J Leukoc Biol (1990) 2.11
One hundred ten consecutive primary orthotopic liver transplants under FK 506 in adults. Transplant Proc (1991) 2.10
A prospective randomized trial of FK506-based immunosuppression after renal transplantation. Transplantation (1995) 2.09
Pathology of human intestinal transplantation. Gastroenterology (1996) 1.98
Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation (1997) 1.98
Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. Transplantation (1991) 1.95
Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. Transplantation (1993) 1.94
Role of murein lipoprotein in morphogenesis of the bacterial division septum: phenotypic similarity of lkyD and lpo mutants. J Bacteriol (1978) 1.94
Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation (1999) 1.93
Sexual lifestyle of long distance lorry drivers in India: questionnaire survey. BMJ (1999) 1.93
Lymphocyte traffic and graft-versus-host disease after fully allogeneic small bowel transplantation. Transplant Proc (1991) 1.89
Effective control of hepatic bleeding with a novel collagen-based composite combined with autologous plasma: results of a randomized controlled trial. Arch Surg (2000) 1.89
Growth of donor-derived dendritic cells from the bone marrow of murine liver allograft recipients in response to granulocyte/macrophage colony-stimulating factor. J Exp Med (1995) 1.88
Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant (2012) 1.88
Logistics and technique for combined hepatic-intestinal retrieval. Ann Surg (1992) 1.85
Microchimerism, dendritic cell progenitors and transplantation tolerance. Stem Cells (1995) 1.83